Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KANAMYCIN SULFATE vs BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing m RNA misreading.
Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of m RNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.
Short-term treatment of serious infections caused by susceptible strains of bacteria (e.g., Escherichia coli, Proteus species, Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species),Adjunctive therapy in staphylococcal infections,Mycobacterium tuberculosis infections (as second-line agent)
Topical treatment of bacterial infections of the skin and eye (e.g., conjunctivitis, keratitis, blepharitis),Prophylaxis of minor wounds, cuts, and abrasions
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (Cr Cl <10 m L/min).
Neomycin: 2-3 h; polymyxin B: 4.5-6 h; bacitracin: 1.5 h. Combined: effectively ~2-6 h depending on renal function; clinical context: prolonged with renal impairment.
Not metabolized; excreted unchanged by glomerular filtration.
Not systemically absorbed after topical administration; no significant metabolism.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Neomycin: ~99% renal; polymyxin B: ~60% renal, 40% fecal; bacitracin: mainly renal (over 90%). Combined: renal (predominant), with minor biliary/fecal contribution (polymyxin B).
Low; approximately 0-10%, primarily to albumin.
Neomycin: 0-20%; polymyxin B: 60-80% (alpha-1-acid glycoprotein, albumin); bacitracin: <5%. Combined: ~40-50% bound overall.
0.2-0.4 L/kg; reflects distribution primarily into extracellular fluid.
Neomycin: ~0.25 L/kg; polymyxin B: ~0.5 L/kg; bacitracin: ~0.3 L/kg. Combined Vd ~0.3-0.5 L/kg, reflecting limited distribution mainly to extracellular fluid.
Intramuscular: ~100%; Oral: <1% (not absorbed); Ophthalmic: minimal systemic absorption (<1%).
Topical/ophthalmic/otic: negligible systemic absorption (<0.1%).
GFR 50-90 m L/min: administer every 24 hours. GFR 10-50 m L/min: administer every 24-72 hours. GFR <10 m L/min: administer every 72-96 hours. Dose adjustments based on serum concentrations.
No systemic absorption with typical topical use; no adjustment necessary. For extensive use on damaged skin, monitor renal function and adjust if needed; no specific GFR-based guidelines.
No dose adjustment required for hepatic impairment. Kanamycin is primarily renally eliminated.
No adjustment needed for topical use. No systemic effects expected.
Neonates: 7.5-10 mg/kg IV every 12 hours. Infants and children: 15 mg/kg/day IM or IV divided every 8-12 hours. Maximum total daily dose: 1.5 g.
Same as adult dosing for topical use. For neonates, use with caution on large surface areas; avoid prolonged use.
Lower initial and maintenance doses due to age-related decrease in renal function. Monitor renal function and serum concentrations closely. Consider dosing based on ideal body weight and renal function.
No specific age-related adjustments. Use with caution on fragile skin; apply sparingly to avoid systemic absorption.
Boxed warnings: Neurotoxicity (ototoxicity vestibular and auditory), nephrotoxicity, and neuromuscular blockade. Risk increases with high doses, prolonged use, renal impairment, and concurrent use of other ototoxic/nephrotoxic drugs. Monitor renal function and drug levels. Avoid in pregnancy.
None.
Ototoxicity (vestibular and auditory) can be irreversible, especially with renal impairment, high doses, prolonged therapy, or concurrent ototoxic drugs. Nephrotoxicity risk; monitor renal function and serum drug levels. Neuromuscular blockade risk, especially with anesthetics, neuromuscular blocking agents, or in patients with neuromuscular disorders. Superinfection, Clostridium difficile diarrhea. Use caution in elderly, dehydration, and pre-existing renal impairment.
Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Neomycin is ototoxic and nephrotoxic if absorbed systemically (e.g., applied to large areas of damaged skin).,Avoid contact with eyes other than for ophthalmic use.,Cross-allergenicity among aminoglycosides exists.
Hypersensitivity to kanamycin or other aminoglycosides; myasthenia gravis (increased risk of neuromuscular blockade).
Hypersensitivity to any component of the product.,Otic use if tympanic membrane is perforated (risk of ototoxicity).
No significant food interactions known. Kanamycin absorption is not affected by food. However, maintain adequate hydration.
No known food interactions with topical application.
First trimester: No evidence of teratogenicity in humans, but crosses placenta and may cause fetal ototoxicity. Second and third trimesters: Risk of fetal ototoxicity (irreversible bilateral hearing loss) and nephrotoxicity, especially with prolonged or high-dose therapy.
No evidence of teratogenicity in first trimester; animal studies show no fetal harm. Second and third trimester risk is low due to minimal systemic absorption from topical use. No known association with congenital anomalies.
Excreted into breast milk in small amounts; M/P ratio not established. Use caution in breastfeeding due to potential for infant ototoxicity and nephrotoxicity; monitor infant for diarrhea, rash, and hearing loss.
Minimal systemic absorption suggests negligible excretion into breast milk; M/P ratio not determined. Considered compatible with breastfeeding by AAP; avoid application to breast area to prevent infant ingestion.
No standard dosing adjustment required for pregnancy; however, increased volume of distribution may require higher loading doses. Tight therapeutic drug monitoring indicated due to altered renal clearance.
No dosage adjustment required for topical use; systemic absorption is negligible. Use standard dosing as per non-pregnant adults.
Kanamycin is an aminoglycoside antibiotic used primarily for serious Gram-negative infections. Monitor peak and trough levels to avoid ototoxicity and nephrotoxicity; typical therapeutic peaks: 15-30 mcg/m L, troughs <5 mcg/m L. Avoid concurrent use with other nephrotoxic or ototoxic drugs (e.g., furosemide, vancomycin, cisplatin). Adjust dose in renal impairment using creatinine clearance. Intramuscular administration preferred; avoid rapid IV push. Use with caution in myasthenia gravis or Parkinson's disease due to neuromuscular blockade potential.
OTC triple antibiotic ointment; avoid use on deep wounds, puncture wounds, or animal bites due to risk of toxicity and lack of efficacy. Neomycin carries the highest risk of allergic contact dermatitis among topical antibiotics; consider patch testing if prolonged use needed. Polymyxin B can cause neurotoxicity and nephrotoxicity if applied to large wounds or damaged skin. Not for use in eyes, ears, or mucous membranes. Do not exceed 7 days of continuous use.
Complete the entire course of therapy even if you feel better.,Report any hearing loss, tinnitus, dizziness, or changes in urination immediately.,Stay well hydrated unless instructed otherwise.,Avoid taking other medications without consulting your doctor, especially diuretics or other antibiotics.,This medication may cause nausea; take with food if tolerated.
Clean the affected area before applying a thin layer of ointment 1-3 times daily.,Do not use on large areas of skin, deep cuts, puncture wounds, or animal bites unless directed by a doctor.,Do not apply to eyes, nose, mouth, or inside ears.,Stop use and consult a doctor if rash or allergic reaction develops, condition worsens, or persists for more than 7 days.,Keep out of reach of children; seek medical attention if accidentally ingested.
"Kanamycin, an aminoglycoside antibiotic, may reduce the renal clearance of Lornoxicam, a nonsteroidal anti-inflammatory drug (NSAID), by competitively inhibiting tubular secretion or altering renal perfusion. This interaction can lead to elevated serum levels of Lornoxicam, increasing the risk of dose-dependent adverse effects such as gastrointestinal bleeding, renal impairment, and central nervous system toxicity. Clinically, patients may present with worsening renal function or NSAID-related side effects, especially in those with pre-existing renal compromise or dehydration."
"Kanamycin, an aminoglycoside antibiotic, increases the nephrotoxic potential of Cisplatin, a platinum-based chemotherapeutic agent, through additive damage to the proximal renal tubules. This synergistic effect elevates the risk of acute kidney injury, particularly in patients with pre-existing renal impairment or those receiving other nephrotoxic drugs. Clinically, this interaction may lead to reduced renal function, electrolyte imbalances, and delayed elimination of both agents, potentially exacerbating systemic toxicity."
"The coadministration of Kanamycin and Vancomycin results in synergistic nephrotoxicity due to additive insult to the proximal renal tubules. Both aminoglycoside and glycopeptide antibiotics accumulate in the renal cortex, causing tubular cell necrosis and acute kidney injury (AKI). This interaction significantly increases the risk of renal impairment, potentially leading to irreversible kidney damage, particularly in patients with pre-existing renal compromise, advanced age, or prolonged therapy."
"Cisatracurium, a non-depolarizing neuromuscular blocking agent (NMBA), competitively blocks nicotinic acetylcholine receptors at the neuromuscular junction, causing skeletal muscle paralysis. Polymyxin B, a polypeptide antibiotic, can potentiate this neuromuscular blockade by reducing presynaptic acetylcholine release and stabilizing postsynaptic membranes, leading to prolonged and enhanced neuromuscular blockade. This interaction increases the risk of prolonged muscle paralysis, respiratory depression, and apnea, especially in patients with renal impairment or those receiving other NMBAs."
"Mecamylamine, a ganglionic blocking agent, potentiates the neuromuscular blocking effects of Polymyxin B, a polypeptide antibiotic. This interaction occurs through additive or synergistic inhibition of neuromuscular transmission, potentially leading to prolonged or intensified muscle relaxation, respiratory depression, and apnea. The clinical outcome may include enhanced toxicity, especially in patients with renal impairment or those receiving concurrent anesthetics or other neuromuscular blocking agents."
"Decamethonium, a depolarizing neuromuscular blocker, enhances the neuromuscular blocking effects of Polymyxin B, a polypeptide antibiotic that can also cause neuromuscular blockade via direct membrane stabilization and calcium channel inhibition. This additive pharmacodynamic interaction can lead to prolonged or enhanced muscle weakness, potentially resulting in respiratory paralysis and apnea. Clinically, this combination increases the risk of acute respiratory failure and may prolong recovery from neuromuscular blockade."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KANAMYCIN SULFATE vs BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, answered by our medical review team.
KANAMYCIN SULFATE is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing m RNA misreading.. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is a Aminoglycoside Antibiotic that works by Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of m RNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KANAMYCIN SULFATE and BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE depend on the specific clinical indication. These are both Aminoglycoside Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KANAMYCIN SULFATE is: 15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.. The standard adult dose of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is: Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining KANAMYCIN SULFATE and BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE. Bacitracin may increase the nephrotoxic activities of Kanamycin. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. KANAMYCIN SULFATE is classified as Category C. First trimester: No evidence of teratogenicity in humans, but crosses placenta and may cause fetal ototoxicity. Second and third trimesters: Risk of fetal ototoxicity (irreversible. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is classified as Category A/B. No evidence of teratogenicity in first trimester; animal studies show no fetal harm. Second and third trimester risk is low due to minimal systemic absorption from topical use. No . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.